Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Get Free Report) Director Melinda Litherland Pei purchased 10,880 shares of the firm's stock in a transaction on Tuesday, December 3rd. The stock was bought at an average cost of $1.00 per share, with a total value of $10,880.00. Following the acquisition, the director now owns 45,180 shares of the company's stock, valued at approximately $45,180. The trade was a 31.72 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Melinda Litherland Pei also recently made the following trade(s):
- On Thursday, December 5th, Melinda Litherland Pei bought 9,120 shares of Rapid Micro Biosystems stock. The stock was purchased at an average cost of $1.04 per share, for a total transaction of $9,484.80.
- On Tuesday, November 26th, Melinda Litherland Pei purchased 108 shares of Rapid Micro Biosystems stock. The shares were purchased at an average cost of $1.04 per share, with a total value of $112.32.
Rapid Micro Biosystems Stock Performance
Rapid Micro Biosystems stock opened at $1.03 on Friday. Rapid Micro Biosystems, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $1.34. The company has a market cap of $44.33 million, a PE ratio of -0.92 and a beta of 1.06. The business's 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $0.86.
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings | Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.
Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last issued its earnings results on Friday, November 1st. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.01). Rapid Micro Biosystems had a negative net margin of 184.93% and a negative return on equity of 48.05%. The firm had revenue of $7.60 million during the quarter, compared to analysts' expectations of $6.30 million. During the same quarter in the prior year, the company earned ($0.31) EPS. As a group, analysts predict that Rapid Micro Biosystems, Inc. will post -1.09 EPS for the current fiscal year.
About Rapid Micro Biosystems
(
Get Free Report)
Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
